94. Katz, D.E., DeLorimier, A.J., Wolf, M.K., Hall, E.R., Cassels, F.J., Van Hamont, J.E., Newcomer, R.L., Davachi, M.A., Taylor, D.N., McQueen, C.E., Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine, 21, 341–346, 2003.
95. Pavot, V., Rochereau, N., Genin, C., Verrier, B., Paul, S., New insights in mucosal vaccine development. Vaccine, 30, 142–154, 2012.
96. Lawson, L.B. and Norton, E.B., Clements, J. D., Defending the mucosa: Adjuvant and carrier formulations for mucosal immunity. Curr. Opin. Immunol., 23, 414–420, 2011.
97. Barba, A.A., Bochicchio, S., Dalmoro, A., Lamberti, G., Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications. Pharmaceutics, 11, 360, 2019.
98. Brigham, K.L., Meyrick, B., Christman, B., Magnuson, M., King, G., Berry, L.C., In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle. Am. J. Med. Sci., 298, 278–281, 1989.
99. Boussif, O., LezoualC’H, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., Behr, J.P., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. U. S. A., 92, 7297–7301, 1995.
100. Albrecht-Buehler, G., The phagokinetic tracks of 3T3 cells. Cell, 11, 395–404, 1977.
101. Bawendi, M.G., Steigerwald, M.L., Brus, L.E., The Quantum Mechanics of Larger Semiconductor Clusters (‘Quantum Dots’). Annu. Rev. Phys. Chem., 41, 477–496, 1990.
102. Parak, W.J., Boudreau, R., Le Gros, M., Gerion, D., Zanchet, D., Micheel, C.M., Williams, S.C., Alivisatos, A.P., Larabell, C., Cell Motility and Metastatic Potential Studies Based on Quantum Dot Imaging of Phagokinetic Tracks. Adv. Mater., 14, 882, 2002.
103. Salahpour Anarjan, F., Active targeting drug delivery nanocarriers: Ligands. Nano-Structures Nano-Objects, 19, 100370, 2019.
104. Agnihotri, J., Saraf., D., Khale, D., Targeting: new potential carriers for targeted drug delivery system. Int. J. Pharm. Sci. Rev. Res., 8, 117–123, 2011.
105. Rani, K. and Paliwal, S., A Review on Targeted Drug Delivery: its Entire Focus on Advanced Therapeutics and Diagnostics. Sch. J. Appl. Med. Sci., 2, 328–331, 2014.
106. Dube, D., Agrawal, G.P., Vyas, S.P., Tuberculosis: From molecular pathogenesis to effective drug carrier design. Drug Discov. Today, 17, 760–773, 2012.
107. Liposomes as drug delivery systems for the treatment of TB. - PubMed - NCBI. 6, 8, 1413–1428, 2011. https://www.ncbi.nlm.nih.gov/pubmed/22026379.
108. Mahato, R.I., Narang, A.S., Thoma, L., Miller, D.D., Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst., 20, 153–214, 2003.
109. Global Nanoparticle Nanomedicine Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2024, Online report. https://www.medgadget.com/2018/12/global-nanoparticle-drug-delivery-market-dosage-price-and-clinical-pipeline-outlook-2024.html.
1 * Corresponding author: [email protected]
3
Nanotools in Customized Drug Delivery System
Thirumalai Subramaniam K J1, Gowthamarajan Kuppusamy2*, Arun Radhakrishnan1 and Veera Venkata Satyanarayana Reddy Karri1
1Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
2Center of Excellence in Nano Science & Technology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India
Abstract
This chapter comprises of the basic information about nano-pharmaceuticals tools in personalized and customized drug delivery system dealing in association with genetic polymorphisms as an introduction, followed by the utility and risk parameters involving the conventional nano drug delivery strategies and their pitfalls. The chapter describes the various nano tools such as polymeric nanoparticles, solid lipid nanoparticle, liposomes, etc. overcoming the available conventional drug delivery strategies. We also discuss nanotechnology as an advance tool in targeting various diseases such as Alzheimer’s and in cancer chemotherapy illustrating in detail to satisfy the current community needs—“Maximum Efficacy: Minimized Side Effect.” It also includes the critical attributes involved in the process of formulation development in respect to customized drug delivery to bypass the rate limiting step associated with protein barriers (which are overexpressed due to specific single nucleotide polymorphism) to get high comfort maximized therapeutic action. This entire chapter will pave a new trend towards the application of nano-pharmaceuticals in the field of novel drug delivery system.
Keywords: Nanotechnology, nano-pharmaceutical tools, nanomedicines, personalized medicine, patient compliance, drug delivery, drug therapy, toxicity
List of Abbreviations
| ADR | Adverse drug reactions |
| ALOX-5 | Arachidonate 5-lipoxygenase |
| AuNP | Gold nanoparticles |
| BBB | Blood brain barrier |
| CNS | Central nervous system |
| CS | Cationic polymer chitosan |
| COX-2 | Cyclooxygenase-2 |
| CYP2D6 | Cytochrome P450 2D6 |
| DNA | Deoxyribonucleic acid |
| FDA | Food and Drug Administration |
| Fe2O3 | Iron(III) oxide or ferric oxide |
| FINGER | Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability |
| MRI | Magnetic resonance imaging |
| MTHFR | Methylenetetrahydrofolate reductase |
| NIR | Near-infrared |
| NMT | Not more than |
| NLC | Nano lipid carrier |
| PPTT | Plasmonic photo thermal therapy |
| RCT | Randomized clinical trials |
| RES |
|